Clinical Trial Update: Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of talazoparib monotherapy for PALB2 mutation-associated advanced breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Talzenna (talazoparib)

Snippet

Sponsor: Stanford University | Conditions: Breast Cancer, Advanced Breast Cancer | Phase 2 | Status: WITHDRAWN